SCHEMBL3340839

SCHEMBL3340839

O=C(NNc1nc2c(s1)Cc1ccccc1-2)c1cc2ccccc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.47
ADORA2A P29274 1/20 0.47
GAA P10253 3/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPK1 P28482 1/20 0.43
BCAT1 P54687 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
LMNA P02545 3/20 0.42
KMT2A Q03164 3/20 0.42
HPGD P15428 2/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
APAF1 O14727 1/20 0.42
POLB P06746 1/20 0.42
CHEK1 O14757 1/20 0.41
DAPK3 O43293 1/20 0.41
LTK P29376 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4801840 0.75 CHEK1 (0.43) ADORA1ADORA2AGAAKDM4EALDH1A1
SCHEMBL3338272 0.74 ADORA1 (0.48) ADORA1ADORA2AKDM4EALDH1A1NPC1
SCHEMBL3340579 0.73 MAPT (0.51) ADORA1ADORA2AGAAKDM4EALDH1A1
SCHEMBL4961278 0.72 MAPT (0.60) ADORA1ADORA2AKDM4EALDH1A1NPC1
SCHEMBL1822988 0.70 MAPT (0.70) ADORA1ADORA2AKDM4EALDH1A1NPC1
SCHEMBL3338990 0.70 CA12 (0.48) GAAKDM4EALDH1A1MAPK1BCAT1
SCHEMBL5574179 0.68 ADORA1 (0.58) ADORA1ADORA2AKDM4EALDH1A1MAPK1
SCHEMBL4960241 0.68 ADORA1 (0.61) ADORA1ADORA2AKDM4EALDH1A1NPC1
SCHEMBL14091298 0.68 ADORA1 (0.58) ADORA1ADORA2AKDM4EALDH1A1NPC1
SCHEMBL4957609 0.67 ADORA1 (0.66) ADORA1ADORA2AKDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA ADORA1 1300/4885ADORA2A 1335/4885GAA 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.